<DOC>
	<DOCNO>NCT02963168</DOCNO>
	<brief_summary>This nonrandomized , open-label , dose escalation , safety , activity , PK study determine MTD optimal dose regimen Oradoxel . No control group include .</brief_summary>
	<brief_title>A DRF Study Evaluate Safety , Tolerability , PK , Activity Oradoxel Monotherapy Subjects w Adv . Malignancies</brief_title>
	<detailed_description>This multicenter , open-label , safety , tolerability , pharmacokinetic , activity study . Eligible subject adult advance solid malignancy . Groups 3 6 subject receive single dose Oradoxel follow toxicity . If non linearity PK observe , additional subject receive Oradoxel 2 single daily dos every three week . Subjects tolerate drug stable disease well response eligible receive ongoing treatment .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Signed write informed consent 2 . ≥18 year age 3 . Histologically cytologically confirm solid tumor metastatic unresectable standard curative palliative measure exist longer effective 4 . Docetaxel monotherapy reasonable treatment judgement Investigator 5 . Measurable disease per RECIST v1.1 criterion 6 . Able swallow oral medication intact dosage form 7 . Adequate hematologic status demonstrate require transfusion support granulocytecolony stimulate factor ( GCSF ) maintain : Absolute neutrophil count ( ANC ) ≥1500 cells/mm3 , Platelet count ≥100 x 109/L , Hemoglobin ( Hgb ) ≥10 g/dL 8 . Adequate liver function demonstrate : Total bilirubin &lt; upper limit normal ( ULN ) , Aspartate transaminase ( AST ) alanine aminotransferase ( ALT ) ≤1.5 × ULN , Alkaline phosphatase ( ALP ) ≤2.5x ULN &lt; 5x ULN bone metastases present , Normal serum albumin 9 . Adequate renal function demonstrate serum creatinine ≤1.5 x ULN creatinine clearance &gt; 60 mL/min calculate Cockroft Gault formula 10 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 11 . Life expectancy least 3 month 12 . Willing fast 6 hour 2 hour Oradoxel administration 13 . Females must postmenopausal ( &gt; 12 month without menses ) surgically sterile ( ie , hysterectomy and/or bilateral oophorectomy ) , sexually active , must use effective contraception ( ie , oral contraceptive , intrauterine device , double barrier method condom spermicide ) agree continue use contraception 30 day last dose study drug . 14 . Sexually active male subject must use barrier method contraception study agree continue use male contraception least 30 day last dose study drug . 1 . Currently take prohibit concomitant medication , premedication , are/is : Strong inhibitor ( eg , ketoconazole ) inducer ( eg , rifampicin St. John 's Wort ) CYP3A4 ( within 2 week prior start dose study ) Strong Pgp inhibitor inducer . Subjects take medication otherwise eligible may enrol discontinue medication ≥1 week dose remain medication end PK sample administration second study treatment An oral medication narrow therapeutic index know Pgp substrate within 24 hour prior start dose study 2 . Unresolved toxicity prior chemotherapy ( subject must recover ≤ Grade 1 toxicity previous anticancer treatment previous investigational product . 3 . Planning receive medical , surgical , radiological cancer treatment course study 4 . Received investigational agent within 14 day 5 halflives prior first study dose day , whichever longer 5 . Require therapeutic use anticoagulant 6 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , clinically significant myocardial infarction within last 6 month , unstable angina pectoris , clinically significant cardiac arrhythmia , bleed disorder , chronic pulmonary disease require oxygen , psychiatric illness/social situation would limit compliance study requirement 7 . Major surgery upper gastrointestinal ( GI ) tract , history GI disease medical condition , opinion Investigator , may interfere oral drug absorption 8 . A known history allergy docetaxel , Cremophor polysorbate 80 ( Tween 80 ) 9 . Evidence fluid retention Screening ( include , example , peripheral edema , pleural effusion , ascites physical radiological examination ) history severe capillary leak syndrome 10 . Any condition Investigator believe would make participation study acceptable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>